Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

Among those with moderate-to-advanced chronic kidney disease, the relationship between blood pressure and cardiovascular disease appears ‘U’-shaped, but is loglinear in apparently healthy adults. The Study of Heart and Renal Protection randomized 9270 patients with chronic kidney disease to simvasta...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Herrington, W, Staplin, N, Judge, P, Mafham, M, Emberson, J, Haynes, R, Wheeler, D, Walker, R, Tomson, C, Agodoa, L, Wiecek, A, Lewington, S, Reith, C, Landray, M, Baigent, C
Формат:	Journal article
Хэвлэсэн:	American Heart Association 2016

Ижил төстэй зүйлс

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
-н: Staplin, N, зэрэг
Хэвлэсэн: (2016)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
-н: Haynes, R, зэрэг
Хэвлэсэн: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
-н: Haynes, R, зэрэг
Хэвлэсэн: (2014)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
-н: Zhu, P, зэрэг
Хэвлэсэн: (2020)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
-н: Storey, B, зэрэг
Хэвлэсэн: (2017)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
-н: Herrington, WG, зэрэг
Хэвлэсэн: (2023)

Evidence for the prevention and treatment of stroke in dialysis patients
-н: Herrington, W, зэрэг
Хэвлэсэн: (2014)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
-н: Zhu, P, зэрэг
Хэвлэсэн: (2020)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
-н: Schlackow, I, зэрэг
Хэвлэсэн: (2017)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
-н: Herrington, W, зэрэг
Хэвлэсэн: (2022)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
-н: Mafham, M, зэрэг
Хэвлэсэн: (2017)

Effects of lowering LDL cholesterol on progression of kidney disease.
-н: Haynes, R, зэрэг
Хэвлэсэн: (2014)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
-н: Mayne, K, зэрэг
Хэвлэсэн: (2024)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
-н: Mihaylova, B, зэрэг
Хэвлэсэн: (2019)

Conventional and genetic evidence on the association between adiposity and CKD
-н: Zhu, P, зэрэг
Хэвлэсэн: (2020)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
-н: Reith, C, зэрэг
Хэвлэсэн: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
-н: Baigent, C, зэрэг
Хэвлэсэн: (2011)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
-н: Mayne, KM, зэрэг
Хэвлэсэн: (2024)

Neprilysin inhibition in chronic kidney disease.
-н: Judge, P, зэрэг
Хэвлэсэн: (2014)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
-н: C. Reith, зэрэг
Хэвлэсэн: (2017-05-01)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
-н: Lamprea-Montealegre, J, зэрэг
Хэвлэсэн: (2019)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
-н: Haynes, R, зэрэг
Хэвлэсэн: (2018)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
-н: Staplin, N, зэрэг
Хэвлэсэн: (2022)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
-н: Mayne, K, зэрэг
Хэвлэсэн: (2023)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
-н: Emberson, JR, зэрэг
Хэвлэсэн: (2010)

Biliary tract and liver complications in polycystic kidney disease
-н: Judge, P, зэрэг
Хэвлэсэн: (2017)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
-н: Staplin, N, зэрэг
Хэвлэсэн: (2023)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
-н: Staplin, N, зэрэг
Хэвлэсэн: (2015)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
-н: Herrington, W, зэрэг
Хэвлэсэн: (2014)

Which cardiovascular risk factors matter in chronic kidney disease?
-н: Baigent, C, зэрэг
Хэвлэсэн: (2007)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
-н: Mafham, M, зэрэг
Хэвлэсэн: (2011)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
-н: Haynes, R, зэрэг
Хэвлэсэн: (2014)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
-н: Herrington, W, зэрэг
Хэвлэсэн: (2018)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
-н: Storey, B, зэрэг
Хэвлэсэн: (2018)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
-н: Donovan, K, зэрэг
Хэвлэсэн: (2022)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
-н: Zhu, D, зэрэг
Хэвлэсэн: (2025)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
-н: Staplin, N, зэрэг
Хэвлэсэн: (2021)

Chronic kidney disease, heart failure and neprilysin inhibition
-н: Haynes, R, зэрэг
Хэвлэсэн: (2019)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
-н: Emberson, J, зэрэг
Хэвлэсэн: (2016)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
-н: Harper, C, зэрэг
Хэвлэсэн: (2021)